7 Matching Annotations
  1. Last 7 days
    1. Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer

      [Paper-level Aggregated] PMCID: PMC7068240

      Evidence Type(s): Prognostic, Oncogenic

      Justification: Prognostic: The study indicates that high miR-31 expression is significantly associated with poorer mortality and shorter median survival time in patients with advanced CRC, suggesting its role as a prognostic biomarker. Oncogenic: The presence of the BRAF V600E mutation is associated with specific tumor characteristics and poorer outcomes, indicating its role in tumorigenesis in colorectal cancer.

      Gene→Variant (gene-first): BRAF(673):V600E BRAF(673):serine/threonine

      Genes: BRAF(673)

      Variants: V600E serine/threonine

    2. Finally, univariate and multivariate analyses were conducted using the Cox-proportional hazards model to determine the factors that influenced poorer outcomes in patients with stage IV CRC (Table II). The univariate anal

      [Paragraph-level] PMCID: PMC7068240 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Prognostic, Oncogenic

      Justification: Prognostic: The passage indicates that the presence of the BRAF V600E mutation correlates with poorer outcomes in patients with stage IV CRC, suggesting its role in prognosis independent of therapy. Oncogenic: The BRAF V600E mutation is associated with tumor development or progression, as indicated by its correlation with poorer prognosis in the context of cancer.

      Gene→Variant (gene-first): 673:V600E

      Genes: 673

      Variants: V600E

    3. To identify miRNAs that were significantly associated with non-MSI tumors containing the BRAF V600E mutation, miRNAs exhibiting no expression among the six CRC tissues and the two corresponding normal colorectal mucosae

      [Paragraph-level] PMCID: PMC7068240 Section: RESULTS PassageIndex: 4

      Evidence Type(s): Diagnostic, Prognostic

      Justification: Diagnostic: The passage discusses the association of the BRAF V600E mutation with non-MSI tumors, indicating its role in classifying or defining a specific subtype of colorectal cancer. Prognostic: The passage mentions that miR-31 is being focused on as a candidate prognostic biomarker, suggesting a correlation with disease outcome in the context of tumors harboring the BRAF V600E mutation.

      Gene→Variant (gene-first): 673:V600E

      Genes: 673

      Variants: V600E

    4. Prior to analyzing the miRNA microarray data, six independent CRC specimens were evaluated according to their KRAS/BRAF mutational profiles and MSI status, which resulted in six subtypes with different genetic and clinic

      [Paragraph-level] PMCID: PMC7068240 Section: RESULTS PassageIndex: 3

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the evaluation of CRC specimens based on their BRAF V600E mutation status, which is used to classify the tumors into different subtypes with distinct genetic and clinical features. Oncogenic: The BRAF V600E mutation is mentioned in the context of tumor specimens, indicating its role in tumor development or progression in colorectal cancer.

      Gene→Variant (gene-first): 673:V600E

      Genes: 673

      Variants: V600E

    5. Identification of miRNAs associated with CRCs expressing the BRAF V600E mutation

      [Paragraph-level] PMCID: PMC7068240 Section: RESULTS PassageIndex: 2

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage indicates that the BRAF V600E mutation is associated with colorectal cancers (CRCs), suggesting its role in defining or classifying a disease subtype. Oncogenic: The mention of the BRAF V600E mutation in the context of colorectal cancers implies that it contributes to tumor development or progression.

      Gene→Variant (gene-first): 673:V600E

      Genes: 673

      Variants: V600E

    6. Colorectal cancer (CRC) manifests after the accumulation of genetic and epigenetic alterations along with tumor microenvironments. MicroRNA (miRNA/miR) molecules have been revealed to serve in critical roles in the progr

      [Paragraph-level] PMCID: PMC7068240 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Prognostic, Diagnostic

      Justification: Prognostic: The passage discusses the association of high miR-31 expression with poorer mortality and shorter median survival time in patients with advanced colorectal cancer, indicating a prognostic relationship. Diagnostic: The study evaluates the potential of miRNAs as biomarkers for colorectal cancer, suggesting that the presence of the BRAF V600E mutation can be used to classify tumors based on miR-31 expression levels.

      Gene→Variant (gene-first): 673:V600E 673:serine/threonine

      Genes: 673

      Variants: V600E serine/threonine

    7. Colorectal cancer (CRC) manifests after the accumulation of genetic and epigenetic alterations along with tumor microenvironments. MicroRNA (miRNA/miR) molecules have been revealed to serve in critical roles in the progr

      [Paragraph-level] PMCID: PMC7068240 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Prognostic, Diagnostic

      Justification: Prognostic: The passage discusses the association of high miR-31 expression with poorer mortality and shorter median survival time in patients with advanced colorectal cancer, indicating a prognostic relationship. Diagnostic: The study evaluates the potential of miRNAs as biomarkers for colorectal cancer, suggesting that the presence of the BRAF V600E mutation can be used to classify tumors based on miR-31 expression levels.

      Gene→Variant (gene-first): 673:V600E 673:serine/threonine

      Genes: 673

      Variants: V600E serine/threonine